India Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

India Diabetes Care Drugs Market is Segmented by Drugs (Oral Anti-Diabetic Drugs, Insulin, Non-insulin Injectable Drugs, And Combination Drugs). The Market Provides the Value (in USD) for the Above-Mentioned Segments.

India Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

India Diabetes Care Drugs Market Size

View Global Report
India Diabetes Care Drugs Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 1.76 Billion
Market Size (2030) USD 2.09 Billion
CAGR (2025 - 2030) 3.50 %

Major Players

India Diabetes Care Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of India Diabetes Care Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

India Diabetes Care Drugs Market Analysis

The India Diabetes Care Drugs Market size is estimated at USD 1.76 billion in 2025, and is expected to reach USD 2.09 billion by 2030, at a CAGR of 3.5% during the forecast period (2025-2030).

According to the study conducted by the Indian Council of Medical Research, India Diabetes (ICMR INDIAB) and published in 2023, the incidence of diabetes stands at 101 million individuals. Diabetes risk factors include race, age, obesity, physical inactivity, a poor diet, behavioral behaviors, genetics, and family history. Controlling blood sugar, blood pressure, and lipid levels can help behavioral behaviors void or postpone the onset of diabetic complications. Diabetes prevention and management pose a significant challenge in India due to several issues and barriers, including a lack of a multisectoral approach, surveillance data, awareness of diabetes, its risk factors and complications, access to health care settings, access to affordable medicines, and so on. 

This increase in the use of diabetes medications in India can be attributed to several factors. Firstly, there has been a growing awareness about diabetes and its complications among the general population, leading to more people seeking medical help and treatment for the condition. Additionally, advancements in diabetes drug treatments have made it easier for healthcare providers to manage the disease effectively.

The availability of a wide range of diabetes medications, including oral medications, insulin injections, and newer classes of drugs such as SGLT-2 inhibitors and GLP-1 receptor agonists, has provided healthcare providers with more options to tailor treatment plans to individual patient needs. This has resulted in better glycemic control and improved outcomes for many diabetic patients.

Furthermore, the increasing prevalence of diabetes in India has also led to a greater emphasis on preventive measures and early intervention, prompting more people to seek medical advice and start treatment at an earlier stage of the disease. This proactive approach has helped to reduce the burden of diabetes-related complications and improve the overall quality of life for diabetic individuals in India.

Overall, the rise in the use of diabetes medications in India is a positive development that reflects the growing awareness and understanding of diabetes as a chronic disease that requires ongoing management and treatment. With continued advancements in diabetes drug treatments and increased access to healthcare services, the diabetic population in India can look forward to better outcomes and improved quality of life in the years to come.

India Diabetes Care Drugs Industry Overview

The India Diabetes Drugs Market is moderately fragmented, with few significant and generic players. The insulin drugs and Sglt-2 drugs market are dominated by a few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, to increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.

India Diabetes Care Drugs Market Leaders

  1. Eli Lilly

  2. Boehringer Ingelheim

  3. Astrazeneca

  4. Sanofi

  5. NovoNordisk

  6. *Disclaimer: Major Players sorted in no particular order
India Diabetes Care Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

India Diabetes Care Drugs Market News

  • March 2023: Sanofi (India) has recently obtained marketing authorization from the Central Drugs Standard Control Organization (CDSCO) for its diabetes medication, Soliqua™. This pre-filled pen drug is specifically designed to enhance glycemic control in adults with type 2 diabetes and obesity who have not achieved sufficient control through oral or injectable therapies. Soliqua™ is administered once daily through pre-filled pens, containing a fixed-ratio combination of insulin glargine and lixisenatide in two different ratios (10-40 and 30-60).
  • November 2022: AstraZeneca India gets approval to market the anti-diabetes drug Dapagliflozin. The company said it had received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes patients with chronic kidney disease (CKD).

India Diabetes Care Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Oral Anti-diabetic drugs
    • 5.1.1 Biguanides
    • 5.1.1.1 Metformin
    • 5.1.2 Alpha-Glucosidase Inhibitors
    • 5.1.2.1 Alpha-Glucosidase Inhibitors
    • 5.1.3 Dopamine D2 receptor agonist
    • 5.1.3.1 Bromocriptin
    • 5.1.4 SGLT-2 inhibitors
    • 5.1.4.1 Invokana (Canagliflozin)
    • 5.1.4.2 Jardiance (Empagliflozin)
    • 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    • 5.1.4.4 Suglat (Ipragliflozin)
    • 5.1.5 DPP-4 inhibitors
    • 5.1.5.1 Onglyza (Saxagliptin)
    • 5.1.5.2 Tradjenta (Linagliptin)
    • 5.1.5.3 Vipidia/Nesina(Alogliptin)
    • 5.1.5.4 Galvus (Vildagliptin)
    • 5.1.6 Sulfonylureas
    • 5.1.6.1 Sulfonylureas
    • 5.1.7 Meglitinides
    • 5.1.7.1 Meglitinides
  • 5.2 Insulins
    • 5.2.1 Basal or Long Acting Insulins
    • 5.2.1.1 Lantus (Insulin Glargine)
    • 5.2.1.2 Levemir (Insulin Detemir)
    • 5.2.1.3 Toujeo (Insulin Glargine)
    • 5.2.1.4 Tresiba (Insulin Degludec)
    • 5.2.1.5 Basaglar (Insulin Glargine)
    • 5.2.2 Bolus or Fast Acting Insulins
    • 5.2.2.1 NovoRapid/Novolog (Insulin Aspart)
    • 5.2.2.2 Humalog (Insulin Lispro)
    • 5.2.2.3 Apidra (Insulin Glulisine)
    • 5.2.3 Traditional Human Insulins
    • 5.2.3.1 Novolin/Actrapid/Insulatard
    • 5.2.3.2 Humulin
    • 5.2.3.3 Insuman
    • 5.2.4 Biosimilar Insulins
    • 5.2.4.1 Insulin Glargine Biosimilars
    • 5.2.4.2 Human Insulin Biosimilars
  • 5.3 Combination drugs
    • 5.3.1 Insulin combinations
    • 5.3.1.1 NovoMix (Biphasic Insulin Aspart)
    • 5.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    • 5.3.1.3 Xultophy (Insulin Degludec and Liraglutide)
    • 5.3.2 Oral Combinations
    • 5.3.2.1 Janumet (Sitagliptin and Metformin)
  • 5.4 Non-Insulin Injectable drugs
    • 5.4.1 GLP-1 receptor agonists
    • 5.4.1.1 Victoza (Liraglutide)
    • 5.4.1.2 Byetta (Exenatide)
    • 5.4.1.3 Bydureon (Exenatide)
    • 5.4.1.4 Trulicity (Dulaglutide)
    • 5.4.1.5 Lyxumia (Lixisenatide)
    • 5.4.2 Amylin Analogue
    • 5.4.2.1 Symlin (Pramlintide)

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetic Population
  • 6.2 Type-2 Diabetic Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Takeda
    • 7.1.2 Novo Nordisk
    • 7.1.3 Pfizer
    • 7.1.4 Eli Lilly
    • 7.1.5 Janssen Pharmaceuticals
    • 7.1.6 Astellas
    • 7.1.7 Boehringer Ingelheim
    • 7.1.8 Merck And Co.
    • 7.1.9 AstraZeneca
    • 7.1.10 Bristol Myers Squibb
    • 7.1.11 Novartis
    • 7.1.12 Sanofi
  • *List Not Exhaustive
  • 7.2 COMPANY SHARE ANALYSIS

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

India Diabetes Care Drugs Industry Segmentation

Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin the body's cells do not respond properly to insulin, or both. India's diabetes care drugs segment market into insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs. The report offers the value (in USD) and volume (in units) for the above segments.

Oral Anti-diabetic drugs Biguanides Metformin
Oral Anti-diabetic drugs Alpha-Glucosidase Inhibitors Alpha-Glucosidase Inhibitors
Oral Anti-diabetic drugs Dopamine D2 receptor agonist Bromocriptin
Oral Anti-diabetic drugs SGLT-2 inhibitors Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Oral Anti-diabetic drugs DPP-4 inhibitors Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Oral Anti-diabetic drugs Sulfonylureas Sulfonylureas
Oral Anti-diabetic drugs Meglitinides Meglitinides
Insulins Basal or Long Acting Insulins Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Insulins Bolus or Fast Acting Insulins NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Insulins Traditional Human Insulins Novolin/Actrapid/Insulatard
Humulin
Insuman
Insulins Biosimilar Insulins Insulin Glargine Biosimilars
Human Insulin Biosimilars
Combination drugs Insulin combinations NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Combination drugs Oral Combinations Janumet (Sitagliptin and Metformin)
Non-Insulin Injectable drugs GLP-1 receptor agonists Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Non-Insulin Injectable drugs Amylin Analogue Symlin (Pramlintide)
Need A Different Region or Segment?
Customize Now

India Diabetes Care Drugs Market Research FAQs

How big is the India Diabetes Care Drugs Market?

The India Diabetes Care Drugs Market size is expected to reach USD 1.76 billion in 2025 and grow at a CAGR of 3.5% to reach USD 2.09 billion by 2030.

What is the current India Diabetes Care Drugs Market size?

In 2025, the India Diabetes Care Drugs Market size is expected to reach USD 1.76 billion.

Who are the key players in India Diabetes Care Drugs Market?

Eli Lilly, Boehringer Ingelheim, Astrazeneca, Sanofi and NovoNordisk are the major companies operating in the India Diabetes Care Drugs Market.

What years does this India Diabetes Care Drugs Market cover, and what was the market size in 2024?

In 2024, the India Diabetes Care Drugs Market size was estimated at USD 1.70 billion. The report covers the India Diabetes Care Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the India Diabetes Care Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

India Diabetes Drugs Industry Report

Statistics for the 2025 India Diabetes Care Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. India Diabetes Care Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.